In addition, because of the co-existence of multiple other dementia-causing brain pathologies in ~70–80% of patients, therapeutic decisions based on selective focus on the load of amyloidβ or tau pathologies, as reflected by levels of blood biomarkers, may be misdirected. The gene discussed is MAPT; the disease is dementia.